List of Excipients in Branded Drug RUGBY MUCUS RELIEF D

« Back to Dashboard

Generic Drugs Containing RUGBY MUCUS RELIEF D

Company	Ingredient	NDC	Excipient
Rugby Laboratories	guaifenesin, pseudoephedrine hydrochloride	0536-1205	CELLULOSE, MICROCRYSTALLINE
Rugby Laboratories	guaifenesin, pseudoephedrine hydrochloride	0536-1205	COPOVIDONE K25-31
Rugby Laboratories	guaifenesin, pseudoephedrine hydrochloride	0536-1205	FD&C YELLOW NO. 6

What are the Most Frequently-Used Excipients in RUGBY MUCUS RELIEF D?

# Of NDCs	Excipient
1	CARBOMER HOMOPOLYMER TYPE B
2	CELLULOSE, MICROCRYSTALLINE
1	COPOVIDONE K25-31

Rugby Mucus Relief D Excipient Strategy and Commercial Opportunities

Last updated: September 9, 2026

Rugby Mucus Relief D is an extended-release combination of guaifenesin and pseudoephedrine hydrochloride, generally marketed as a store-brand OTC product for chest congestion and nasal congestion. Its commercial position depends less on active-ingredient exclusivity than on reliable controlled release, tablet robustness, abuse-deterrence compliance for pseudoephedrine, retail distribution, and low-cost manufacturing.

The principal formulation opportunity is to preserve 12-hour delivery while reducing tablet size, improving swallowability, limiting moisture sensitivity, and enabling differentiated dosage forms. Because guaifenesin and pseudoephedrine are established OTC actives, the strongest commercial advantages are likely to come from excipient engineering, packaging, supply reliability, and private-label channel strategy rather than composition-of-matter patents.

What is Rugby Mucus Relief D?

Rugby Mucus Relief D is a private-label OTC expectorant and nasal decongestant product. Public product descriptions identify the active ingredients as:

Attribute	Product information
Product	Rugby Mucus Relief D
Active ingredients	Guaifenesin and pseudoephedrine hydrochloride
Typical strength	Guaifenesin 600 mg and pseudoephedrine HCl 60 mg
Dosage form	Extended-release oral tablet
Therapeutic use	Chest congestion and nasal congestion
Product category	OTC combination drug
Commercial model	Store brand, institutional, and pharmacy distribution
Likely dosing concept	12-hour extended release
Key regulatory constraints	FDA OTC drug requirements and federal pseudoephedrine controls

Guaifenesin is an expectorant that increases hydration of respiratory secretions. Pseudoephedrine is an alpha-adrenergic decongestant that reduces nasal mucosal swelling. FDA recognizes both ingredients in OTC monograph conditions for their respective uses, subject to applicable labeling, dosage, and combination requirements.[1][2]

The exact excipient composition can vary by manufacturer, contract manufacturer, product presentation, and manufacturing revision. Product labels typically identify inactive ingredients such as microcrystalline cellulose, hypromellose, povidone, crospovidone, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, and stearic acid in comparable extended-release tablets. The commercial analysis below focuses on the functional excipient classes required for this product type.

What excipients are likely used in Rugby Mucus Relief D?

The formulation requires excipients that support high drug loading, extended release, tablet compression, coating, and chemical stability.

Excipient class	Likely function in the product	Commercial relevance
Hypromellose	Hydrophilic matrix former and release-rate controller	Controls 12-hour release and supports regulatory comparability
Microcrystalline cellulose	Diluent and compression aid	Improves tablet hardness and manufacturing throughput
Povidone	Binder and granulation aid	Supports uniformity in a high-load tablet
Crospovidone or sodium starch glycolate	Disintegrant	Promotes dispersion of the matrix after hydration
Colloidal silicon dioxide	Glidant and moisture-management aid	Improves powder flow and reduces manufacturing variability
Magnesium stearate	Lubricant	Supports ejection but requires control to avoid slowing dissolution
Stearic acid	Lubricant or matrix modifier	Can affect wetting and release behavior
Film-coating polymers	Appearance, handling, taste masking, and moisture protection	Enables differentiation and improves patient acceptance

The principal technical issue is balancing the high mass of guaifenesin with the smaller quantity of pseudoephedrine. A formulation with excessive binder or hydrophobic lubricant can produce slow or variable dissolution. A formulation with insufficient matrix former can release pseudoephedrine too quickly, creating an undesirable early concentration spike and failure against the intended extended-release profile.

How does the excipient strategy control extended release?

The most commercially practical approach is a hydrophilic polymer matrix, usually based on hypromellose or a related cellulose ether. After ingestion, the tablet hydrates and forms a gel layer. Drug release occurs through a combination of polymer swelling, diffusion, and gradual erosion.

A successful matrix must meet four requirements:

1. Maintain a reproducible release profile across the 12-hour dosing interval.
2. Prevent dose dumping under accelerated agitation or alcohol-containing media.
3. Tolerate normal variation in compression force and tablet porosity.
4. Remain manufacturable at high guaifenesin loading.

A higher-viscosity hypromellose grade generally produces slower release, but it can increase tablet size and compression force. Lower-viscosity grades may improve processability but create a greater risk of rapid release. Blending polymer grades can provide a more controllable profile than using a single polymer.

Which formulation variables create the greatest risk?

The highest-risk variables are:

• Hypromellose concentration and viscosity grade.
• Tablet porosity and compression force.
• Particle-size distribution of guaifenesin.
• Lubrication time and magnesium stearate concentration.
• Granulation endpoint and residual moisture.
• Coating weight and film permeability.
• Excipient lot-to-lot variability.
• Dissolution performance after storage under heat and humidity.

Guaifenesin’s high dose makes particle engineering important. Smaller particles may improve content uniformity and compaction but can increase surface area and alter dissolution. Granulation can improve flow and compressibility, but over-granulation may reduce matrix hydration and create release variability.

What excipient improvements could create commercial opportunities?

The clearest opportunities involve lower-cost reformulation, patient convenience, and manufacturing resilience.

Smaller tablets and improved swallowability

Guaifenesin creates a substantial tablet-mass burden. High-functionality diluents and directly compressible excipients may reduce granulation requirements and improve tablet tensile strength. A smaller tablet could support premium private-label positioning, especially for older adults and patients who have difficulty swallowing large extended-release tablets.

Potential strategies include:

• Higher-density microcrystalline cellulose systems.
• Silicified microcrystalline cellulose for improved flow and compaction.
• Co-processed excipients combining filler and binder functions.
• Granulated guaifenesin with optimized particle-size distribution.
• Reduced lubricant levels supported by improved tooling and process control.

The commercial value is greater in e-commerce and pharmacy channels, where product differentiation is possible. Mass retail channels remain highly price sensitive.

Improved moisture and heat stability

Extended-release matrices can be sensitive to humidity. Moisture uptake may change tablet hardness, swelling, dissolution, and coating adhesion. Excipient and packaging changes can reduce stability risk:

• Low-moisture excipient grades.
• Moisture-barrier film coatings.
• High-barrier blister packaging.
• Induction-sealed bottles with desiccant systems.
• Nitrogen-flushed packaging for selected presentations.

A lower-cost formulation that requires less protective packaging could reduce total cost of goods. Conversely, a premium moisture-resistant version could support distribution in hot and humid markets.

Alcohol-resistant release

Extended-release products face scrutiny regarding rapid drug release in the presence of ethanol. A polymer matrix should be screened in alcohol-containing dissolution media. Polymer blends, insoluble barriers, or multiparticulate systems can reduce the risk of alcohol-induced dose dumping.

This area has commercial value because an improved in-vitro release profile can support formulation robustness and reduce post-market quality risk. It does not necessarily create strong patent protection unless the composition or process is novel and non-obvious.

Taste and sensory improvement

The product is swallowed as a tablet, so taste masking is less important than for syrups, chewables, and orally disintegrating tablets. It becomes important if the product is extended into pediatric or dysphagia-friendly formats.

Film coating can reduce the perception of bitterness from pseudoephedrine and improve tablet handling. A polymeric coating also supports color, product identification, and moisture protection.

What dosage-form opportunities exist beyond the current tablet?

The product’s active ingredients support several line-extension strategies, but each creates regulatory and formulation complexity.

Opportunity	Technical rationale	Commercial assessment
Smaller 12-hour tablet	Reduces swallowability burden	Strongest near-term opportunity
Film-coated tablet	Improves handling and moisture resistance	Low-to-moderate differentiation
Caplet	Easier swallowing and recognizable OTC format	Practical private-label extension
Single-dose blister	Supports travel and compliance	Useful for convenience channels
Liquid formulation	Supports pediatric and dysphagia markets	Difficult because of taste, stability, and dose-volume issues
Chewable product	Differentiates administration	Taste masking and dose uniformity are significant hurdles
Multiparticulate capsule	May improve release control	Higher manufacturing and packaging costs
Guaifenesin-only product	Avoids pseudoephedrine restrictions	Broad retail opportunity but less differentiated
Pseudoephedrine-free decongestant combination	Avoids pharmacy-counter controls	Requires a different active-ingredient strategy

A guaifenesin-only extended-release product may offer the largest volume opportunity because it avoids pseudoephedrine purchase restrictions and associated retail controls. The combination product retains value for consumers seeking both chest and nasal congestion relief, but its distribution is more constrained.

What is the FDA regulatory status of Rugby Mucus Relief D?

The active ingredients are established OTC substances. Guaifenesin and pseudoephedrine products are generally regulated under FDA OTC monograph conditions or through approved applications depending on the specific product and marketing pathway.[1][2]

The key regulatory questions are:

• Whether the exact strength and combination comply with the applicable OTC monograph.
• Whether the extended-release dosage form satisfies applicable performance and labeling requirements.
• Whether the product is marketed under an approved application, monograph pathway, or another permitted OTC framework.
• Whether the product has an FDA listing and current manufacturing registration.
• Whether the label complies with pseudoephedrine controls and required warnings.

The product name alone does not establish a unique FDA application number, manufacturer, or Orange Book listing. Store-brand products can be sourced from different contract manufacturers under different National Drug Codes.

What is the Orange Book and patent status of Rugby Mucus Relief D?

Rugby Mucus Relief D is unlikely to depend on a new chemical entity patent estate. Guaifenesin and pseudoephedrine are long-established active ingredients, and the main competitive barriers are formulation know-how, manufacturing controls, regulatory compliance, and distribution.

Orange Book status

The Orange Book primarily lists approved prescription drug products and patents submitted by applicants. A conventional OTC monograph product is generally not protected through the same Orange Book framework as a branded prescription drug.[3]

For this product category, the practical exclusivity analysis is:

Protection type	Relevance
Composition-of-matter patent	Minimal for established actives
New formulation patent	Possible but difficult to establish broad protection
Method-of-use patent	Limited for conventional OTC indications
Orange Book-listed patent	Not expected to be the main barrier
OTC monograph compliance	Central regulatory requirement
Manufacturing know-how	Important commercial barrier
Retail and pharmacy contracts	Major market-access barrier
Pseudoephedrine controls	Significant distribution constraint

A formulation patent could cover a specific polymer ratio, release profile, particle-size range, coating system, or manufacturing process. Such protection would be narrower than a new chemical entity patent and could be designed around through alternative excipients or process conditions.

When does Rugby Mucus Relief D lose exclusivity?

Rugby Mucus Relief D does not appear to have a conventional prescription-style exclusivity date that determines market entry. Its active ingredients are already broadly available in generic and store-brand products.

Market exclusivity is therefore commercial rather than statutory. It can be lost when:

• A retailer replaces the product with a lower-cost supplier.
• A competing private label improves tablet size or packaging.
• A manufacturer experiences a shortage or quality recall.
• A new formulation offers a more convenient dosing format.
• Consumers shift from pseudoephedrine combinations to phenylephrine or non-decongestant products.
• A guaifenesin-only product captures demand from consumers who do not need pseudoephedrine.

Are Paragraph IV challenges relevant to Rugby Mucus Relief D?

Paragraph IV litigation is generally associated with abbreviated new drug applications referencing patents listed for approved prescription products. It is not the normal competitive mechanism for an OTC monograph store-brand product.

A Paragraph IV challenge could become relevant if the product were tied to an approved application containing listed formulation or method patents. For a conventional OTC guaifenesin-pseudoephedrine product, competition is more likely to occur through parallel monograph-compliant products, private-label substitution, formulation improvements, and contract manufacturing bids.

What manufacturing and intellectual-property barriers matter most?

The strongest barriers are operational rather than patent-based.

Manufacturing barriers

Manufacturers must manage:

• High active-ingredient loading.
• Uniform blending of low-dose pseudoephedrine with high-dose guaifenesin.
• Controlled granulation and compression.
• Reproducible extended-release dissolution.
• Moisture and temperature stability.
• Pseudoephedrine inventory controls.
• Secure warehousing and pharmacy-channel distribution.
• Packaging that limits diversion and supports required sales procedures.

Pseudoephedrine controls under federal law require regulated retail handling, sales tracking, quantity limits, and identity verification.[4] These rules raise operational costs and reduce the number of retail channels available for the product.

Intellectual-property barriers

Potentially protectable areas include:

• Specific hypromellose blends.
• Alcohol-resistant extended-release matrices.
• Low-dose pseudoephedrine dispersion within a high-dose guaifenesin matrix.
• Moisture-resistant coating systems.
• Reduced-size tablets with equivalent dissolution.
• Multiparticulate release systems.
• Manufacturing methods that reduce weight variation.
• Packaging and dispensing systems designed for controlled pharmacy distribution.

Broad claims covering ordinary use of hypromellose, microcrystalline cellulose, or magnesium stearate would face validity and obviousness risks. Narrow claims tied to measurable release performance, unusual excipient ratios, or a defined manufacturing sequence would be more defensible but easier for competitors to design around.

How does Rugby Mucus Relief D compare with competing products?

Product category	Main advantage	Main limitation	Excipient opportunity
Guaifenesin-only extended release	No pseudoephedrine purchase controls	Does not relieve nasal congestion	Smaller tablet and lower-cost matrix
Guaifenesin plus pseudoephedrine	Combined chest and nasal relief	Pharmacy-counter restrictions	Release control and compliant packaging
Immediate-release combination	Lower manufacturing complexity	More frequent dosing	Better patient convenience through extended release
Liquid combination	Flexible dosing	Taste, stability, and larger package size	Taste masking and preservative systems
Branded extended-release product	Consumer recognition	Higher price	Premium coating, packaging, and dosage form
Store-brand extended-release product	Low price and retailer control	Limited brand loyalty	Cost reduction and supply reliability

The most direct competition comes from private-label guaifenesin-pseudoephedrine extended-release tablets and branded extended-release combination products. The strongest differentiators are price, availability, tablet size, package count, and retailer placement.

Which commercial opportunities are most attractive?

1. Private-label reformulation

A smaller, more robust tablet with equivalent release performance could win retailer contracts. The opportunity is strongest where the manufacturer can reduce manufacturing cost without increasing packaging requirements.

2. Guaifenesin-only line extension

A guaifenesin-only product broadens distribution beyond pseudoephedrine-controlled channels. It can be sold in more retail formats and may support larger package counts.

3. Pharmacy and institutional supply

Hospitals, clinics, correctional facilities, and long-term-care providers may value standardized, low-cost products with reliable supply. Packaging, unit-dose presentation, and electronic ordering can matter more than consumer branding.

4. Seasonal inventory programs

Cold and flu products experience demand volatility. A manufacturer with flexible capacity, stable excipient sourcing, and short lead times can capture seasonal private-label business.

5. Excipient supplier partnerships

Suppliers can position high-functionality excipients around:

• Direct compression.
• Moisture control.
• Smaller tablet size.
• Alcohol-resistant release.
• Reduced dissolution variability.
• Lower lubricant sensitivity.
• Improved high-dose API processing.

The strongest value proposition is demonstrated performance in a guaifenesin-heavy extended-release matrix rather than generic claims about excipient functionality.

What revenue exposure does the product create?

Revenue exposure is driven by volume, retailer contracts, seasonality, and supply continuity. Public product-level revenue for Rugby Mucus Relief D is not generally disclosed because Rugby is a private-label business rather than a separately reported branded franchise.

The commercial risk profile is:

Risk	Impact
Pseudoephedrine regulation	Limits distribution and raises handling costs
Seasonal demand	Creates inventory and capacity volatility
Retailer concentration	A lost contract can materially reduce volume
API or excipient shortage	Can interrupt supply during peak demand
Product recall	Can damage retailer relationships and increase returns
Price competition	Compresses margins rapidly
Formulation failure	Can trigger dissolution or stability problems
Consumer substitution	Can shift demand to guaifenesin-only products

For investors and suppliers, the most relevant metric is not brand-level sales but contracted volume, retailer concentration, gross margin after compliance costs, and the manufacturer’s ability to produce multiple OTC products on the same equipment.

Key Takeaways

• Rugby Mucus Relief D is an extended-release guaifenesin and pseudoephedrine hydrochloride OTC product.
• Its core excipient strategy likely relies on a hydrophilic polymer matrix, compression aids, binders, disintegrants, glidants, lubricants, and protective coating materials.
• Hypromellose selection, tablet porosity, lubrication, and moisture control are the main formulation variables.
• The best near-term opportunity is a smaller, more robust extended-release tablet with equivalent dissolution and lower manufacturing cost.
• Guaifenesin-only line extensions may offer broader distribution because they avoid pseudoephedrine sales controls.
• Orange Book patents and Paragraph IV litigation are unlikely to be the primary competitive issues for a conventional OTC monograph product.
• Manufacturing know-how, supply reliability, retailer contracts, packaging, and pseudoephedrine compliance are more important barriers.
• A patent strategy would be strongest around defined release profiles, excipient ratios, alcohol resistance, particle engineering, or manufacturing methods.
• Public product-level revenue and a single definitive excipient formula are not established solely by the Rugby product name.

FAQs About Rugby Mucus Relief D

Can Rugby Mucus Relief D be reformulated with different excipients?

Yes. A reformulation can use alternative binders, matrix polymers, diluents, lubricants, or coating systems if the product remains compliant with the applicable FDA pathway and maintains required quality and dissolution performance.

Is hypromellose essential for Rugby Mucus Relief D?

No. Hypromellose is a common extended-release polymer, but other hydrophilic or polymeric matrix systems may be technically feasible. Any substitute must reproduce the intended release profile and stability characteristics.

Could a smaller tablet be patented?

Possibly, but a patent would need claims directed to a novel and non-obvious combination of composition, structure, process, or release performance. Tablet size alone would rarely provide strong protection.

Does pseudoephedrine make the product harder to commercialize?

Yes. Federal purchase limits, sales tracking, identity verification, inventory controls, and pharmacy-counter distribution increase operating requirements and restrict channels compared with guaifenesin-only products.

What is the strongest substitute for Rugby Mucus Relief D?

The closest substitutes are other extended-release guaifenesin-pseudoephedrine tablets. Guaifenesin-only extended-release products are the strongest commercial substitutes when consumers do not require a systemic nasal decongestant.

References

1. U.S. Food and Drug Administration. (n.d.). 21 CFR Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. Electronic Code of Federal Regulations.

2. U.S. Food and Drug Administration. (2023). Over-the-counter monograph M012: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Drug Enforcement Administration. (n.d.). Combat methamphetamine epidemic act requirements for retail sales of pseudoephedrine. DEA.